CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Malalagama, Geethal N.; Chryssidis, Steve; Parnis, Francis

doi:10.1186/s40644-017-0119-3

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven plasma metabolites of cabazitaxel are detected 116 . Cabazitaxel is mainly excreted through faeces and a minor percentage through kidney 117 .…”

Section: Fig 7: Schematic Representation Of Mode Of Action Of Taxanementioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

Taxol is an important drug used for the treatment of various types of cancer. It is primarily obtained from Taxus brevifolia bark and has a long history of the developmental program of 50 years. It functions as a microtubule-stabilizing compound and inhibits mitosis of cancer cells, thereby providing a protective role in the treatment of cancers. In addition to it, taxol also interferes with a number of biochemical pathways and protein to bring about apoptosis and cell death. Since its inception, taxol has undergone various levels of modifications and formulations with a motive of making its action more effective. This has led to the development of Paclitaxel by Bristol-Myers Squibb for large scale commercialization. Consequently other semi-synthetic variants such as Docetaxel and Cabazitaxel were also developed for better actions. All these compounds are collectively called as Taxanes and contain a common ringed baccatin III structure in its molecule. This review is an attempt to illustrate the gradual development of anticancer taxanes from its precursor Taxol and its various pharmacological activities against the treatment of cancer. An extensive literature survey has been made to compile all the relevant information in relation to its development and pharmacological activity. Taxanes can be very well utilized in the treatment of various types of cancers. More clinical trials are a requirement of time for effective refinement of taxanes for the benefit of cancer patients. INTRODUCTION: From Nature to Laboratory: Taxol (generic name paclitaxel) is a microtubule-stabilizing drug used for the treatment of breast, ovarian, and lung cancer and is approved by food and drug administration, United States of America in the year 1992 1 .

show abstract

“…Seven plasma metabolites of cabazitaxel are detected 116 . Cabazitaxel is mainly excreted through faeces and a minor percentage through kidney 117 .…”

Section: Fig 7: Schematic Representation Of Mode Of Action Of Taxanementioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

show abstract

“…Case reports of hemorrhagic cystitis, which may be due to radiation recall in patients with history of pelvic irradiation. High rates of grade 3/4 neutropenia in clinical trials [97,141,213] 28 RPLS has occurred rarely in trials. Monitor for headache, seizure, lethargy, and hypertension.…”

Section: Toxicities Of Anticancer Therapymentioning

confidence: 99%

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Rivera

Bryan

et al. 2018

Oncologic Critical Care

View full text Add to dashboard Cite

Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies.Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.

show abstract

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Rivera

Do²,

Bryan³

et al. 2019

Oncologic Critical Care

View full text Add to dashboard Cite

Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.

show abstract

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Cited by 4 publications

References 6 publications

Untitled

Untitled

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Contact Info

Product

Resources

About